Although GSK-3β depletion didn’t affect p53-null colon cancer cell lines, it has been demonstrated that GSK-3β silencing sensitized chemoresistant p53-null colon cancer cells to antitumor effects of DNA–damaging drugs26. The gene discussed is GSK3B; the disease is colonic neoplasm.